The head of the Kuedinsky Municipal District of Perm Krai, Florid Badrtdinov, reported at a regional government meeting on the plans of Indian investor Rajesh Sharma to develop pharmaceutical production in Kueda. In 2026–2030, the company "Advanced-Perm," which is controlled by the businessman, intends to invest 595 million rubles in the modernization and expansion of the existing facility.
The investment project involves the reconstruction of a plant for the production of parenteral drugs, which has been operating in Kueda since 2013. The plan includes updating production capacities and technological equipment, as well as creating new high-tech jobs.
Perm Krai Governor Dmitry Mahonin emphasized the region's interest in further developing pharmaceutical production. According to him, regional authorities have already provided the enterprise with support on infrastructure issues, including water supply, and expect stable development of the site and an increase in production.
The company became unprofitable starting from 2015 and was acquired by the "Advanced" Group of Companies in January 2019. After the change in ownership, a program for reconstruction and restoration of economic efficiency was announced. Rajesh Sharma, CEO of GC "Advanced" and a representative of the Indian business alliance, had previously announced plans for the development of the pharmaceutical plant.
According to "Rusprofile," Rajesh Sharma owns 99% of the shares in LLC "Advanced-Perm," while the remaining 1% is held by LLC "Advanced Trading." The company's general director is Inna Pestova. As of the end of 2024, the company's revenue amounted to 148.2 million rubles, with a net profit of 34.6 million rubles.
The "Advanced" Group of Companies specializes in the production and distribution of medications for treating tuberculosis, HIV/AIDS, hepatitis, and other socially significant diseases.
Regional authorities expect that the implementation of the project will strengthen Perm Krai's position in the pharmaceutical industry in the medium term.
Indian pharmaceutical companies are showing varied dynamics in their projects in Russia. For instance, Jodas Expoim continues construction of its production complex in the Voskresensk district of Moscow Oblast, despite regulatory violations and complaints about some of its products on the Russian market. Completion of the plant is scheduled for the third quarter of 2026.
Meanwhile, some Indian investors have paused their announced projects. At the end of 2025, Cadila Pharmaceuticals froze construction of a pharmaceutical complex and injection drug plant in Kemerovo Oblast. The project, worth approximately 10 billion rubles, introduced in 2024 and implemented jointly with the Russian Direct Investment Fund (RDIF), was expected to produce over 1 billion units of medication and up to 1,500 tons of active pharmaceutical ingredients (API).
Additionally, at the beginning of 2026, construction of a pharmaceutical complex and API factory in Murmansk Oblast, announced in 2023, effectively stopped. Regional authorities cited difficulties in cooperation with the investor. The project of the company "SafFarm," controlled by Indian Safecon Lifesciences and Eniker Bio Science, was valued at more than 9.2 billion rubles.
Source: VADEMECUM
